Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Videla

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Translational Neurodegeneration|May 9, 2023
Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementiaNuole Zhu, Miguel Santos-Santos, Ignacio Illán-Gala, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|August 4, 2020
Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderlyJordi Pegueroles, Adriana Pané, Eduard Vilaplana, et al.
JAMA Network Open|August 5, 2022
Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down SyndromeLaura Videla, Bessy Benejam, Jordi Pegueroles, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 11, 2023
Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer's disease in adults with Down syndromeLaura Videla, Bessy Benejam, María Carmona-Iragui, et al.
Neurology|December 17, 2024
Posterior Cortical Atrophy Due to Alzheimer Disease in a Person With Down Syndrome: A Case ReportÍñigo Rodríguez-Baz, Bessy Benejam, Alejandra O Morcillo-Nieto, et al.
Alzheimer'S Research & Therapy|June 29, 2021
VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndromeAlberto Lleó, Maria Carmona-Iragui, Laura Videla, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 3, 2025
Generational effects in Down syndrome: Enriched environment enhances functionality without reducing Alzheimer's disease riskLídia Vaqué-Alcázar, Laura Videla, Bessy Benejam, et al.
JAMA Network Open|May 23, 2022
Association of Alzheimer Disease With Life Expectancy in People With Down SyndromeMaria Florencia Iulita, Diana Garzón Chavez, Maria Klitgaard Christensen, et al.
Alzheimer'S Research & Therapy|February 2, 2022
The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 aloneConstance Delaby, Teresa Estellés, Nuole Zhu, et al.
Neurology|September 11, 2020
Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuumIgnacio Illán-Gala, Victor Montal, Jordi Pegueroles, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Translational Neurodegeneration|May 9, 2023
Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementiaNuole Zhu, Miguel Santos-Santos, Ignacio Illán-Gala, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|August 4, 2020
Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderlyJordi Pegueroles, Adriana Pané, Eduard Vilaplana, et al.
JAMA Network Open|August 5, 2022
Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down SyndromeLaura Videla, Bessy Benejam, Jordi Pegueroles, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 11, 2023
Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer's disease in adults with Down syndromeLaura Videla, Bessy Benejam, María Carmona-Iragui, et al.
Neurology|December 17, 2024
Posterior Cortical Atrophy Due to Alzheimer Disease in a Person With Down Syndrome: A Case ReportÍñigo Rodríguez-Baz, Bessy Benejam, Alejandra O Morcillo-Nieto, et al.
Alzheimer'S Research & Therapy|June 29, 2021
VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndromeAlberto Lleó, Maria Carmona-Iragui, Laura Videla, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 3, 2025
Generational effects in Down syndrome: Enriched environment enhances functionality without reducing Alzheimer's disease riskLídia Vaqué-Alcázar, Laura Videla, Bessy Benejam, et al.
JAMA Network Open|May 23, 2022
Association of Alzheimer Disease With Life Expectancy in People With Down SyndromeMaria Florencia Iulita, Diana Garzón Chavez, Maria Klitgaard Christensen, et al.
Alzheimer'S Research & Therapy|February 2, 2022
The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 aloneConstance Delaby, Teresa Estellés, Nuole Zhu, et al.
Neurology|September 11, 2020
Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuumIgnacio Illán-Gala, Victor Montal, Jordi Pegueroles, et al.
Pageof 9